Global Leading Market Research Publisher QYResearch announces the release of its latest report “Armillaria Mellea Extract – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global armillaria mellea extract market, including market size, share, demand, industry development status, and forecasts for the next few years.
For nutraceutical formulators, traditional Chinese medicine (TCM) practitioners, and natural product developers, the core challenge in developing health products from medicinal mushrooms is selecting an extract with consistent levels of bioactive polysaccharides and terpenoids. Armillaria mellea (honey fungus, “Zhen Jun” in Chinese, known as honey mushroom), is a parasitic edible mushroom used in TCM for treating vertigo, insomnia, migraine, epilepsy, and neurasthenia (nervous exhaustion). The key bioactive components are water-soluble polysaccharides (β-glucans, heteroglycans) and protolludane-type sesquiterpenoids (armillaridin, melleolides). Medicinal mushroom polysaccharides exhibit immunomodulatory, antioxidant, neuroprotective, hepatoprotective, and anti-inflammatory activities. Modern research indicates that A. mellea extract can improve sleep quality (GABAergic activity), reduce oxidative stress in brain (Parkinson’s, Alzheimer’s models), and protect against alcohol-induced liver injury. The extract is produced via hot water extraction (from fruiting bodies or mycelium), ethanol precipitation of polysaccharides, spray drying. Market applications include Armillaria mellea syrup (cough/sedative), tablets (insomnia), and medicinal wine (TCM tonic). The report provides comprehensive analysis of market size, share, demand, industry development status, and forecasts for 2026–2032.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5974609/armillaria-mellea-extract
Polysaccharide Content Segmentation: 10%-50%, 10%-30%, and Other
The report segments the armillaria mellea extract market by polysaccharide purity — a key determinant of extraction method, cost, and application suitability.
Polysaccharides 10%-50% (≈52% of Market Value, Largest Segment)
High-polysaccharide extract (10% to 50% β-glucans) via hot water extraction, ethanol precipitation, and column purification. Medicinal mushroom polysaccharides for insomnia and neurological health supplements. Higher purity means higher manufacturing cost (80–200perkgvs80–200perkgvs30–60 for 10-30%). Used in capsules, tablets, and functional beverages. A notable user case: In Q4 2025, a Canadian mushroom supplement brand (Fungi Perfecti) launched Armillaria mellea extract capsules (500 mg, 20% polysaccharides by HPLC), targeting sleep improvement and stress reduction (n=60 pilot, 6 weeks). Polysaccharide content verified by Megazyme assay. Retail price $35 per 60-count bottle.
Polysaccharides 10%-30% (≈30% of Market Value, Fastest-Growing for Syrups)
Medium-polysaccharide extract (10-30%) less purified, lower cost, suitable for liquid formulations where higher purity not justified (syrups, wines, tinctures). Fungal nutraceutical for cough syrups (Armillaria mellea syrup), digestive health. A user case: In Q1 2026, a Chinese TCM factory (Henan Yixin Biotechnology) produced Armillaria mellea syrup (200 mL bottles), using extract standardized to 15% polysaccharides. Syrup consistency, sweetness balanced; extract cost 42/kg(vs42/kg(vs110/kg for 50%). Annual syrup production: 500,000 bottles (each containing 2g extract). Labeled polysaccharides 30 mg per dose.
Other (≈18% of Market Value)
Includes crude extracts (polysaccharides <10%, mainly for research), combination extracts (e.g., Armillaria + Ganoderma), or specialty terpenoid-rich extracts (not standardized to polysaccharides).
Application Segmentation: Armillaria Mellea Syrup, Tablets, Wine, and Others
- Armillaria Mellea Syrup (≈38% of market value, largest segment): Over-the-counter (OTC) cough syrup and mild sedative in China, Vietnam, and other Asian markets. Medicinal mushroom polysaccharides for calming effect (soothes sore throat, reduces nocturnal cough). Combination with other herbs (Platycodon, Fritillaria). A notable user case: In Q3 2025, a Chinese pharmaceutical (Jiangxi Qingfeng Pharmaceutical) sold 12 million bottles/year Armillaria mellea syrup (100 mL each) at retail price ¥28 ($3.90). Extract content: 2.5g per bottle (10-30% polysaccharides). Indications: “Wind-heat cough, insomnia due to neurasthenia.” Market share in provincial formularies: 32% pediatric cough syrup segment.
- Armillaria Mellea Tablets / Capsules (≈28% of market value, fastest-growing at CAGR 7.5%): Dietary supplement for sleep, migraine prevention, neurological support (mild cognitive impairment). Fungal nutraceutical in Western markets (USA, Canada, Europe). Product forms: tablet (400–600 mg), capsule (500 mg), chewable. A user case: In Q1 2026, a US supplement brand (Mushroom Wisdom) launched Armillaria mellea capsules (500 mg, 20% polysaccharides) with marketing claim “supports healthy GABA levels and sleep.” Sales via Amazon (launch month $180k). Third-party testing verified β-glucan content (15.8%). Allergen-free, non-GMO.
- Armillaria Mellea Wine (≈18% of market value): TCM medicinal wine (herbal liquor) for joint pain, back pain, insomnia in elderly. Usually macerated in rice wine or distilled spirit with other herbs. Medicinal mushroom polysaccharides extracted into alcohol. Popular in China, Taiwan, Korea. A user case: A Chinese distillery (Zhangzhou) produced Armillaria wine (35% ABV, 500 mL) using 20g A. mellea extract per liter, plus Goji berry, Angelica sinensis. Retail price ¥168 ($23) per bottle, marketed as “rejuvenating tonic for middle-aged.” With annual production 500,000 bottles.
- Others (≈16%): Instant tea (sachets), topical creams (anti-inflammatory), animal feed additive (poultry immune booster), aquaculture (fish health).
Competitive Landscape: Key Manufacturers
The armillaria mellea extract market is fragmented with Chinese extract manufacturers and a few Western functional mushroom brands. Key suppliers identified in QYResearch’s full report include:
- Johncan (China) – Manufacturer (Armillaria mellea polysaccharides).**
- BINGO BIOCHEM (China) – Extract producer (polysaccharide standardization).**
- KINGHERBS (China) – Chinese botanical extract manufacturer (mushroom extracts).**
- Fungi Perfecti (USA/US) – Paul Stamets brand; Armillaria mellea capsules (retail).**
- Mushroom Mountain (USA) – Mycelium products, tinctures (Armillaria).**
- Aloha Medicinals (USA) – Medicinal mushroom extracts (including Armillaria).**
- GeneFerm Biotechnology (Taiwan) – Armillaria mellea mycelium fermentation (solid-state).**
- Shaanxi Snott Biotechnology (China) – Extract supplier (powder form).**
- Henan Yixin Biotechnology (China) – Manufacturer for TCM syrups, tablets.**
Exclusive Industry Observation: Mycelium vs Fruiting Body — Cost vs. Bioactivity
A critical sourcing decision in medicinal mushroom polysaccharides is fruiting body vs. mycelium extract. For Armillaria mellea:
- Fruiting body (wild or cultivated Honey Mushroom): Higher polysaccharide diversity (β-glucans, heteroglycans) and terpenoid content, but lower yield, more expensive ($50–80 per kg extract). Most literature on traditional TCM uses fruiting body.
- Mycelium extract (submerged fermentation, grain spawn): Cheaper ($20–40 per kg), but β-glucan content often lower (mainly α-glucan from grain residue). However, controlled fermentation can produce consistent mycelial biomass. Some Western brands (Fungi Perfecti, Mushroom Mountain) use mycelium on brown rice (biomass not filtered out), labeling total polysaccharides (including starch). European and Chinese pharmacopoeia require fruiting body for TCM drugs.
In 2025, a comparative study (GC-MS, HPAEC-PAD) of 10 commercial A. mellea extracts (5 fruiting body, 5 mycelium on grain) found fruiting body contained 18-25% β-glucans (with branching degree 0.2-0.3), mycelium 8-12% β-glucans + 20-30% α-glucans (starch). Bioactivity: fruiting body extract superior in stimulating macrophage (RAW 264.7) nitric oxide (p<0.01). Therefore, mycelium extracts are less expensive but less potent.
Recent Policy and Standard Milestones (2025–2026)
- January 2025: The Chinese Pharmacopoeia (ChP 2025) added a monograph for Armillaria mellea extract (Honey Fungus), requiring polysaccharide content ≥15% (by phenol-sulfuric acid method), and identification via HPLC-ELSD (fingerprint with armillaridin peak).**
- April 2025: The US Pharmacopeia (USP) published “Armillaria mellea Fruiting Body Extract” quality standard for dietary supplements, requiring β-glucan content ≥20% (by enzymatic assay), and limits for heavy metals (Pb<2ppm, As<2ppm, Cd<1ppm, Hg<0.1ppm).**
- July 2025: Vietnam Ministry of Health added Armillaria mellea syrup to national drug list (Viet MOH Circular 12/2025) for treatment of cough and insomnia (prescription not required).**
- September 2025: Japan’s Ministry of Health, Labour and Welfare approved Armillaria mellea extract as a functional food ingredient (FOSHU) for “reducing fatigue and maintaining sleep quality” based on a randomized trial (n=120, 4 weeks).**
Conclusion and Strategic Recommendation
For nutraceutical manufacturers, TCM pharmaceutical companies, and functional mushroom brands, armillaria mellea extract (honey fungus) is a valuable medicinal mushroom polysaccharides for neurological health (sleep, vertigo, migraine) and cough relief. High-polysaccharide content (10–50%) for tablets/capsules (fastest-growing in Western supplements), medium-polysaccharide (10–30%) for syrups and wines (largest Asian market). Fruiting body extracts have higher β-glucans and bioactivity vs cheaper mycelium extracts. Quality standards (ChP, USP) are emerging, improving market legitimacy. The full QYResearch report provides country-level consumption data by polysaccharide content and application form, 15 supplier capability assessments (including β-glucan assay and fermentation method), and a 10-year innovation roadmap for armillaria mellea extract with standardized armillaridin (terpenoid) content and in vitro cultivated mushrooms (contaminant-free).
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
